Published in Lancet Oncol on October 01, 2010
Pamidronate Prophylaxis in Multiple Myeloma 30 mg/Month Versus 90 mg/Month | NCT00376883
International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation. J Clin Oncol (2014) 1.52
Epidemiology and pathogenesis of osteonecrosis of the jaw. Nat Rev Rheumatol (2011) 1.35
International Myeloma Working Group recommendations for the treatment of multiple myeloma-related bone disease. J Clin Oncol (2013) 1.19
Optimising the use of bone-targeted agents in patients with metastatic cancers: a practical guide for medical oncologists. Support Care Cancer (2011) 1.17
Diagnosis and treatment of bone disease in multiple myeloma: spotlight on spinal involvement. Scientifica (Cairo) (2013) 1.15
International Myeloma Working Group recommendations for global myeloma care. Leukemia (2013) 1.10
European Myeloma Network Guidelines for the Management of Multiple Myeloma-related Complications. Haematologica (2015) 0.94
Management of multiple myeloma in older adults: Gaining ground with geriatric assessment. J Geriatr Oncol (2016) 0.84
Bone disease in multiple myeloma and precursor disease: novel diagnostic approaches and implications on clinical management. Expert Rev Mol Diagn (2011) 0.84
Health-related quality of life in patients with multiple myeloma--does it matter? Haematologica (2015) 0.79
Decreasing frequency of osteonecrosis of the jaw in cancer and myeloma patients treated with bisphosphonates: the experience of the oncology network of piedmont and aosta valley (north-Western Italy). ISRN Oncol (2013) 0.76
Growth differentiation factor 15 (GDF15) promotes osteoclast differentiation and inhibits osteoblast differentiation and high serum GDF15 levels are associated with multiple myeloma bone disease. Haematologica (2015) 0.76
Bones, breasts, and bisphosphonates: rationale for the use of zoledronic acid in advanced and early breast cancer. Breast Cancer (Dove Med Press) (2011) 0.75
Intravenous pamidronate for myeloma bone disease: can the dose be lowered? Lancet Oncol (2010) 0.75
Mortality in randomized trials of antioxidant supplements for primary and secondary prevention: systematic review and meta-analysis. JAMA (2007) 11.87
International staging system for multiple myeloma. J Clin Oncol (2005) 11.29
Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study. BMJ (2008) 11.08
Association of funding and conclusions in randomized drug trials: a reflection of treatment effect or adverse events? JAMA (2003) 8.21
European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood (2013) 8.00
Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD). Cochrane Database Syst Rev (2015) 7.31
Antioxidant supplements for prevention of gastrointestinal cancers: a systematic review and meta-analysis. Lancet (2004) 6.35
Perioperative beta blockers in patients having non-cardiac surgery: a meta-analysis. Lancet (2008) 5.05
Peginterferon alpha-2a is associated with higher sustained virological response than peginterferon alfa-2b in chronic hepatitis C: systematic review of randomized trials. Hepatology (2010) 4.19
Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis. J Clin Epidemiol (2007) 4.06
Transarterial (chemo)embolisation for unresectable hepatocellular carcinoma. Cochrane Database Syst Rev (2011) 3.73
Influence of reported study design characteristics on intervention effect estimates from randomized, controlled trials. Ann Intern Med (2012) 3.63
Risk of monoclonal gammopathy of undetermined significance (MGUS) and subsequent multiple myeloma among African American and white veterans in the United States. Blood (2005) 3.25
Carotid artery stenting vs carotid endarterectomy: meta-analysis and diversity-adjusted trial sequential analysis of randomized trials. Arch Neurol (2010) 2.83
Antihypertensive drugs and risk of cancer: network meta-analyses and trial sequential analyses of 324,168 participants from randomised trials. Lancet Oncol (2010) 2.77
Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases. Cochrane Database Syst Rev (2012) 2.74
Vitamin D supplementation for prevention of mortality in adults. Cochrane Database Syst Rev (2011) 2.72
Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia. J Clin Oncol (2009) 2.68
Segmentation-based detection of allelic imbalance and loss-of-heterozygosity in cancer cells using whole genome SNP arrays. Genome Biol (2008) 2.67
Normalization of Illumina Infinium whole-genome SNP data improves copy number estimates and allelic intensity ratios. BMC Bioinformatics (2008) 2.66
Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse. Blood (2011) 2.66
Apparently conclusive meta-analyses may be inconclusive--Trial sequential analysis adjustment of random error risk due to repetitive testing of accumulating data in apparently conclusive neonatal meta-analyses. Int J Epidemiol (2008) 2.66
Trial sequential analysis reveals insufficient information size and potentially false positive results in many meta-analyses. J Clin Epidemiol (2008) 2.61
Risk of acute myeloid leukemia and myelodysplastic syndromes after multiple myeloma and its precursor disease (MGUS). Blood (2011) 2.54
Primary chronic cold agglutinin disease: a population based clinical study of 86 patients. Haematologica (2006) 2.50
Common variants at 2q37.3, 8q24.21, 15q21.3 and 16q24.1 influence chronic lymphocytic leukemia risk. Nat Genet (2010) 2.45
Inflammatory response after open heart surgery: release of heat-shock protein 70 and signaling through toll-like receptor-4. Circulation (2002) 2.44
Estimating required information size by quantifying diversity in random-effects model meta-analyses. BMC Med Res Methodol (2009) 2.39
Distinct patterns of hematopoietic stem cell involvement in acute lymphoblastic leukemia. Nat Med (2005) 2.36
Addiction to c-MYC in multiple myeloma. Blood (2012) 2.35
Melphalan and prednisone plus thalidomide or placebo in elderly patients with multiple myeloma. Blood (2010) 2.33
Can trial sequential monitoring boundaries reduce spurious inferences from meta-analyses? Int J Epidemiol (2008) 2.31
Autoimmune and chronic inflammatory disorders and risk of non-Hodgkin lymphoma by subtype. J Natl Cancer Inst (2006) 2.23
Treatment in a specialised out-patient mood disorder clinic v. standard out-patient treatment in the early course of bipolar disorder: randomised clinical trial. Br J Psychiatry (2013) 2.22
No major differences in 30-day outcomes in high-risk patients randomized to off-pump versus on-pump coronary bypass surgery: the best bypass surgery trial. Circulation (2010) 2.21
Targeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitus. Cochrane Database Syst Rev (2013) 2.18
The validity of EORTC QLQ-C30 fatigue scale in advanced cancer patients and cancer survivors. Palliat Med (2003) 2.18
Stereotyped B-cell receptors in one-third of chronic lymphocytic leukemia: a molecular classification with implications for targeted therapies. Blood (2012) 2.14
The journal impact factor as a predictor of trial quality and outcomes: cohort study of hepatobiliary randomized clinical trials. Am J Gastroenterol (2005) 2.12
FGFR3 dysregulation in multiple myeloma: frequency and prognostic relevance. Br J Haematol (2002) 2.07
The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approach. Nat Rev Clin Oncol (2012) 2.05
[Bisphosphonate-associated osteonecrosis of the jaw in patients with multiple myeloma]. Ugeskr Laeger (2009) 2.03
The number of patients and events required to limit the risk of overestimation of intervention effects in meta-analysis--a simulation study. PLoS One (2011) 2.02
Vitamin D supplementation for prevention of mortality in adults. Cochrane Database Syst Rev (2014) 2.01
[Survival after high-dose therapy with autologous stem cell support]. Tidsskr Nor Laegeforen (2004) 1.97
High response rate and durable remissions following fludarabine and rituximab combination therapy for chronic cold agglutinin disease. Blood (2010) 1.91
Arterial and venous thrombosis in monoclonal gammopathy of undetermined significance and multiple myeloma: a population-based study. Blood (2010) 1.89
Effect of hepatitis B immunisation in newborn infants of mothers positive for hepatitis B surface antigen: systematic review and meta-analysis. BMJ (2006) 1.88
Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemia. Blood (2008) 1.87
Banding ligation versus beta-blockers as primary prophylaxis in esophageal varices: systematic review of randomized trials. Am J Gastroenterol (2007) 1.86
Disclosure of investigators' recruitment performance in multicenter clinical trials: a further step for research transparency. PLoS Med (2011) 1.86
Randomised controlled trial of total compared with subtotal hysterectomy with one-year follow up results. BJOG (2003) 1.82
A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony-stimulating factor: significant effects on quality of life. Br J Haematol (2003) 1.81
Deep vein thrombosis after monoclonal gammopathy of undetermined significance and multiple myeloma. Blood (2008) 1.78
Subsets with restricted immunoglobulin gene rearrangement features indicate a role for antigen selection in the development of chronic lymphocytic leukemia. Blood (2004) 1.77
Compassionate use of interventions: results of a European Clinical Research Infrastructures Network (ECRIN) survey of ten European countries. Trials (2010) 1.77
Commentary: The evolution of methods to assess the effects of treatments, illustrated by the development of treatments for diphtheria, 1825-1918. Int J Epidemiol (2011) 1.76
Evaluating complex interventions in end of life care: the MORECare statement on good practice generated by a synthesis of transparent expert consultations and systematic reviews. BMC Med (2013) 1.76
Targeting p53 in vivo: a first-in-human study with p53-targeting compound APR-246 in refractory hematologic malignancies and prostate cancer. J Clin Oncol (2012) 1.74
Combination of pegylated IFN-α2b with imatinib increases molecular response rates in patients with low- or intermediate-risk chronic myeloid leukemia. Blood (2011) 1.71
Rituximab for primary chronic cold agglutinin disease: a prospective study of 37 courses of therapy in 27 patients. Blood (2003) 1.69
Thalidomide for previously untreated elderly patients with multiple myeloma: meta-analysis of 1685 individual patient data from 6 randomized clinical trials. Blood (2011) 1.69
Intensive therapy for multiple myeloma in patients younger than 60 years. Long-term results focusing on the effect of the degree of response on survival and relapse pattern after transplantation. Haematologica (2006) 1.68
Quality of life and body image for bladder cancer patients undergoing radical cystectomy and urinary diversion--a prospective cohort study with a systematic review of literature. Urology (2009) 1.67
Thalidomide for treatment of multiple myeloma: 10 years later. Blood (2008) 1.66
Screening for copy-number alterations and loss of heterozygosity in chronic lymphocytic leukemia--a comparative study of four differently designed, high resolution microarray platforms. Genes Chromosomes Cancer (2008) 1.66